Valuation: ACLS THER

Market Cap 715M 621M 577M 532M 1B 68.27B 1.02B 6.83B 2.67B 33.91B 2.69B 2.63B 114B P/E 2026 *
-7.89x
P/E 2027 * -6.43x
Enterprise Value 579M 503M 467M 431M 812M 55.32B 827M 5.53B 2.17B 27.48B 2.18B 2.13B 92.4B EV / Sales 2026 *
101x
EV / Sales 2027 * 110x
Free-Float
97.72%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 56 2024-01-16
President 67 2024-11-17
Director of Finance/CFO 39 2022-12-31
Director TitleAgeSince
Chairman 56 2022-12-31
Director/Board Member 50 2014-08-31
Director/Board Member 59 2016-08-31
Change 5-day change 1-year change 3-year change Capi.($)
-3.74%-1.56%+45.14%+64.45% 55.2B
-0.81%-0.33%+27.15%+81.12% 55.6B
-0.05%+0.93%-15.57%-14.66% 23.51B
-1.87%-5.70%-3.70%+358.53% 22.35B
-4.01%-2.68%+12.50%-12.70% 20.6B
-1.23%-3.15%+26.00%-33.84% 17.45B
-3.34%-6.96%+22.02%+515.48% 15.16B
+1.19%+0.25%+51.38%+183.05% 13.91B
-5.09%-13.14%+151.85%+272.20% 13.74B
Average -2.05%-1.55%+35.20%+157.07% 26.39B
Weighted average by Cap. -2.07%-0.46%+31.15%+122.04%

Financials

2026 *2027 *
Net sales 5.71M 4.96M 4.61M 4.25M 8M 545M 8.15M 54.55M 21.36M 271M 21.45M 20.98M 911M 5.36M 4.65M 4.32M 3.99M 7.51M 512M 7.64M 51.17M 20.03M 254M 20.12M 19.68M 854M
Net income -84.78M -73.64M -68.39M -63.07M -119M -8.09B -121M -810M -317M -4.02B -318M -311M -13.52B -103M -89.04M -82.69M -76.26M -144M -9.79B -146M -979M -383M -4.86B -385M -377M -16.35B
Net Debt -136M -118M -109M -101M -190M -12.95B -193M -1.29B -507M -6.43B -509M -498M -21.62B -125M -108M -101M -92.91M -175M -11.92B -178M -1.19B -467M -5.92B -469M -459M -19.92B
Logo ACLS THER
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing novel small and large molecule product candidates for immuno-inflammatory diseases. Its proprietary KINect drug discovery platform coupled with its integrated discovery approach to small and large molecules enables the Company to identify and advance product candidates. It provides contract research services to third parties enabled by its early-stage research and development expertise. The contract research segment is engaged in the provision of laboratory services. Its product candidate pipeline includes Bosakitug (ATI-045), ATI-2138 and ATI-052. The Bosakitug (ATI-045) is an investigational, novel, humanized anti-Thymic stromal lymphopoietin (TSLP) monoclonal antibody that specifically binds to human TSLP, blocking its interaction with the receptor complex and disrupting signal transduction. Its other investigational product candidate is Lepzacitinib (ATI-1777).
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-